Markets:

Overview

News

Currencies

International

Treasuries

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

248.78 -4.64 (-1.83%)

Streaming Delayed Price Updated: 11:12 AM EDT, Jul 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - Ordinary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >

Ascendis Pharma (ASND) Shows High Growth Momentum With Bull Flag Breakout Setup ↗

July 20, 2026

Via Chartmill

ASCENDIS PHARMA A/S (NASDAQ:ASND) Screens as a High-Growth Momentum Candidate ↗

May 18, 2026

Via Chartmill

What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗

May 14, 2026

Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.

Via The Motley Fool

Topics Regulatory Compliance

Energy Fund Yielding 7% and Up 14% in a Year Still Wasn’t Enough to Stop This $3 Million Exit ↗

May 09, 2026

The Kayne Anderson Energy Infrastructure Fund targets U.S. energy infrastructure, emphasizing income from MLPs and related equities.

Via The Motley Fool

Topics Regulatory Compliance

Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss ↗

February 11, 2026

Via Chartmill

Topics Earnings

ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum ↗

January 28, 2026

Via Chartmill

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

A Look Ahead: Ascendis Pharma's Earnings Forecast ↗

November 11, 2025

Via Benzinga

Ascendis (ASND) Q1 2026 Earnings Call Transcript ↗

May 08, 2026

Ascendis (ASND) Q1 2026 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity

April 13, 2026

In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL...

Via MarketMinute

Topics Economy

Agriculture Stock Up 53% Draws $12 Million Bet. Here's What Long-Term Investors Should Know ↗

March 20, 2026

This agribusiness firm delivers grain, renewables, and plant nutrient solutions to commercial and industrial clients worldwide.

Via The Motley Fool

Topics Regulatory Compliance

Ascendis (ASND) Q4 2025 Earnings Call Transcript ↗

February 23, 2026

Ascendis (ASND) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗

February 22, 2026

Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions.

Via The Motley Fool

Topics Regulatory Compliance

Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗

February 22, 2026

Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.

Via The Motley Fool

Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗

February 22, 2026

Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗

February 22, 2026

Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector.

Via The Motley Fool

Topics Regulatory Compliance

Ascendis Pharma (ASND) Q4 2025 Earnings Transcript ↗

February 11, 2026

Ascendis Pharma (ASND) Q4 2025 Earnings Transcript

Via The Motley Fool

Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan ↗

December 25, 2025

Ascendis Pharma (ASND) meets Mark Minervini's strict criteria, showing a powerful technical uptrend paired with explosive revenue growth over 269%.

Via Chartmill

Why Dyne Therapeutics Stock Was Crushing it This Week ↗

November 21, 2025

The company has solid potential with its development of drugs targeting muscle disorders.

Via The Motley Fool

Topics Artificial Intelligence

European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility

November 19, 2025

European American Depositary Receipts (ADRs) have recently experienced a period of significant fluctuation, reflecting a broader climate of market volatility that has ripple across global financial...

Via MarketMinute

Topics Artificial Intelligence Economy Supply Chain

Ascendis (ASND) Q3 2025 Earnings Call Transcript ↗

November 13, 2025

Ascendis (ASND) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

November 12, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗

October 29, 2025

Via Benzinga

Looking Into Ascendis Pharma AS's Recent Short Interest ↗

October 21, 2025

Via Benzinga

Ascendis Pharma A/S - ADR (NASDAQ:ASND) Shows Strong Growth Momentum in Technical and Fundamental Analysis ↗

October 14, 2025

Ascendis Pharma (ASND) is a high-growth stock with strong technical uptrends and impressive fundamentals, including surging revenue and earnings momentum.

Via Chartmill

What Does the Market Think About Ascendis Pharma AS? ↗

September 29, 2025

Ascendis Pharma AS's (NYSE: ASND) short interest as a percent of float has fallen 14.63% since its last report. According to exchange reported data, there are now 2.29 million shares sold short, which...

Via Benzinga

$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today ↗

September 25, 2025

Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past 10 years by 13.64% on an annualized basis producing an average annual return of 26.77%. Currently, Ascendis Pharma has a market...

Via Benzinga

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment ↗

September 08, 2025

BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study.

Via Benzinga

$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today ↗

September 08, 2025

Via Benzinga

Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗

September 04, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Delivering useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments.

Newsletters

The top stories, industry insights and relevant research, assembled by our editors and delivered to your inbox.

Connect

http://www.facebook.com/pages/Cabling-Installation-and-Maintenance/298118662118

https://www.instagram.com/cim_magazine/

https://www.linkedin.com/company/3962332

http://twitter.com/CABLINGMAG

Affiliated Brands

DATA CENTER FRONTIER

ISE

LIGHTWAVE

DIGITAL INFRASTRUCTURE GROUP

About Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions